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To improve the quality of care for patients with cardiovascular disease, three evidence-based metrics were 
researched and reviewed. These metrics were for patients with ischemic vascular disease (IVD) for whom an 
antiplatelet medication is recommended, patients with coronary artery disease (CAD) and either left ventricular 
systolic dysfunction (LVSD) or diabetes mellitus for whom ACE inhibitors/ARBs are recommended, and patients 
with congestive heart failure (CHF) and LVSD for whom beta-blockers are recommended. The goals were to 
identify patients from the Lehigh Valley Physician’s Group (LVPG) whose care was not in compliance with these 
guidelines, standardize the documentation of allergies, contraindications, and intolerances to improve the accuracy 
of the metrics, and educate providers to prescribe the medications when appropriate. The most common reason for 
gaps in documented care was found to be the lack of transferred medication lists from CPO to EPIC approximately 6 
months post-implementation of the new EMR. Other reasons included many relative contraindications for which 
providers could receive credit for through appropriate documentation. Through extensive chart review and “registry 
clean-up”, team-based care supported by the creation of sustainable workflow process, and provider and medical 
staff education, an increase in the percentage of patients meeting metric guidelines within specific practices was 
achieved. The increase varied between practices: 5.9-27.64% for antiplatelet use in patients with IVD documented, 
8.3-16.3% for beta-blocker use in CHF, and 4.1% for ACE/ARBs. 
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Introduction 
Cardiovascular disease and stroke are the 
leading cause of death both in the United States and 
globally.
1,2
 The medical costs for these illnesses reach 
into the hundreds of billions of dollars annually
4
. On 
a local level, more than 1 in 4 deaths in Pennsylvania 
are attributed to heart disease.
5
  The coronary heart 
disease (CHD) death rate for from 2008-2012 was 
found to be 99.2 per 100,000 people in Lehigh 
County and 107.4 per 100,000 in Northampton 
County
5
, both major regions from which LVPG 
draws its patients. Although the human and financial 
cost of CVD is shocking, these numbers have 
decreased by more than 60% since 1950.
1
 This is 
largely the result of public health efforts and 
standardized care protocols, including use of aspirin, 
angiotensin-converting enzyme inhibitors/angiotensin 
receptor blockers (ACE inhibitors/ARBs), and beta-
blockers for secondary prevention, showing that 
adherence to evidence-based guidelines can hugely 
impact hospitals and patients alike. 
Medicare’s Shared Savings Program, in 
which LVHN participates, requires Accountable Care 
Organizations (ACOs) to demonstrate adherence to 
thirty-three quality standards tracked by each ACO
3
. 
Among these thirty-three metrics are those examined 
in this project, specifically chosen to focus on 
outpatient cardiac health. The first metric includes 
patients with a diagnosis of IVD 18 years or older 
with documented use of aspirin or other antiplatelet 
agent. The goal for the organization, based on 
national benchmarks, is to ensure greater than 77.7% 
of patients with IVD are on anti-platelet therapy
3
. 
The second metric includes patients with a diagnosis 
of CHF and LVSD, defined as an ejection fraction 
less than 40%, who are taking a beta-blocker; the 
goal is to have more than 83.4% of patients in 
adherence
3
. The final metric includes patients with a 
diagnosis of CAD as well as diabetes mellitus (DM) 
or left ventricular systolic dysfunction (LVSD) who 
are taking an ACE inhibitor or ARB. The goal for 
this metric is 70.8%
3
. 
For the metrics chosen, it is important to 
note that certain exclusion criteria are allowable 
under Medicare. While there are no exclusions for the 
anti-platelet metric, the beta-blocker metric allows 
exceptions for medication allergy, contraindication, 
2 
or intolerance, such as low blood pressure, asthma, or 
patient refusal of the medication. Medicare also 
specifies similar exclusions for the ACE 
inhibitor/ARB metric. 
Despite strong evidence in support of 
aspirin, beta-blockers and ACE/ARBs, the American 
College of Cardiology’s Practice Innovation and 
Clinical Excellence outpatient registry shows that 
only 66.5% of cardiac patients receive the optimal, 
evidence-based combination of medications.
4
 Our 
hope is to improve adherence to the aforementioned 
evidence-based standards of care within LVPG. 
 
Methods 
We used a LEAN approach to develop small 
tests of change within several practices. Our initial 
plan was to review charts and provide data to 
practices to assist them in a focused medication 
reconciliation. We were also testing whether this 
would be reflected by improvement in the dashboards 
on EPIC. Data was collected through patient chart 
review using the EPIC electronic medical record. 
Reports for each quality metric were generated using 
the My Report feature on EPIC. The antiplatelet 
quality metric was reviewed first. Reports were run 
for each of 7 practices within LVPG for the 
“antiplatelet use--not met” criterion. When the 
number of patients was too large to effectively search 
an additional narrowing criterion was added (i.e. 
patients' most recent beta-blocker prescription) to 
identify patients who had not been seen in the 
practice in >6 months. The chart of each patient listed 
on the report was then reviewed systematically. To 
summarize findings, a Microsoft Excel spreadsheet 
was constructed listing MRN, age of patient, date of 
upcoming appointments at that specific practice, date 
of last appointment at that practice, the practice 
name, PCP, cardiologist (if applicable), and whether 
the medications had been transferred from the CPO 
EMR, previously used by LVHN. If the patient’s 
medication list had been transferred into EPIC from 
CPO and they were not currently on aspirin, past 
appointment notes, problem lists, and medications 
were investigated to determine the possible reasoning 
for not prescribing aspirin. Possible contraindications 
were recorded in the spreadsheet. These included 
simultaneous use of a blood thinner, history of 
hemorrhage, GI bleed/ulcer, possible fall risk, a 
diagnosis of severe kidney disease, use of NSAIDs, 
chronic steroid use, aspirin allergy, and any 
intolerance to aspirin. Color coding was used to 
organize data, specifically patients who had not been 
seen in one year, patients with medication list not 
transferred, and patients needing to be removed from 
the IVD registry due to improper diagnosis or false 
listing by the EMR.   
A connection was then made with a 
registered nurse, clinical coordinator, or care 
manager in each practice. Individual meetings with 
the contacts for each practice were arranged and the 
Excel spreadsheet for their practice reviewed. The 
contact person then proceeded to reconcile 
medication lists as necessary, contact providers to 
review certain patients, and properly document 
allergies and intolerances. We found that medical 
staff often did not know how to properly document 
allergies, intolerances, and patient declinations in 
EPIC, so a step-by-step PowerPoint explaining the 
documentation processes was created as an 
educational tool. Additionally, providers and medical 
staff were taught how to view their practice metrics 
and run reports for their practice or specific patients. 
Individual practice graphs of the metric compliance 
were viewed on a weekly basis to track progress. 
The same procedure was followed for the 
review of patients requiring a beta-blocker 
prescription. A similar Excel spreadsheet was used, 
with contraindications specific to beta-blockers, 
including bradycardia, hypotension, allergy, and 
intolerance such as lightheadedness or fatigue. One 
practice was reviewed. An additional practice was 
instructed on how to run the report themselves and 
the update charts as needed. 
 While attempting to repeat the process for 
patients needing ACE inhibitor/ARB prescriptions, it 
was discovered that the EPIC report captured patients 
with CAD and LVSD, but not those with CAD and 
DM. This overlooked approximately 90% of patients 
needing an ACE/ARB. For this reason, the metric 
was not extensively reviewed at the practice level. 
We worked with information services to update this 
metric in EPIC has since been updated, which can 
now be reviewed by practices in the future. 
In an effort to make the project sustainable 
and ensure that quality metrics are appropriately 
addressed in the future, a workflow and other 
educational tools were created for the process 





Anti-platelet Quality Metric 
Practices reviewed for the anti-platelet quality metric 
were Hamilton Internal Medicine, Cedar Crest 
Internal Medicine, LVPG Family and Internal 
Medicine Bethlehem Township, Lehigh Valley 
Physician’s Practice, Emmaus Family Medicine, 
Cedar Crest Cardiology, Cedar Crest Family 
Medicine, and Hamburg Cardiology. A total of 733 
charts were reviewed with 320/733 or 43.7% not 
currently or previously taking aspirin. The average 
increase in the anti-platelet metric was 11.0%.
 
 
Table 1: Summary of Data for All Practices for Anti-platelet Quality Metric 
Possible Clinical and 
Pharmaceutical 
Contraindications 
Percentage of Total 
Patients Reviewed 
Percentage of Patients Not 
Currently/Previously on Anti-
platelet 
On a blood thinner 31.4% 46.9% 
History of Hemorrhage 7.5% 11.6% 
GI Bleed/Ulcer 7% 10% 
Fall Risk 7.4% 9.7% 
Severe Kidney Disease 10% 14.4% 
Use of NSAIDs 5.9% 6.3% 
Chronic Steroid Use 5.2% 8.1% 
Allergy 5.2% N/A 
Aspirin listed in past notes 45.4% N/A 
Procedural Issues Percentage of Total Patients 
Reviewed 
Medications not transferred 39.8% 
No upcoming appointment 51.7% 
Patients not seen in the past year 14.6% 





Figure 1: Percentage of Patients on Anti-platelet for 3080 Hamilton Internal Medicine The percentage of patients 
on anti-platelet began at 70.3% and ended at 82.1%, an increase of 11.8%. The goal of 77.7% was met. Intervention 





Figure 2: Percentage of Patients on Anti-platelet for 1230 Cedar Crest Internal Medicine The percentage of 
patients on anti-platelet began at 72.1% and ended at 75.9%, an increase of 3.8% No patient data was inputted into 





Figure 3: Percentage of Patients on Anti-platelet for LVPG Family and Internal Medicine Bethlehem Township The 
percentage of patients on anti-platelet began at 63.7% and ended at 71.3%, an increase of 7.6%. Intervention 





Figure 4: Percentage of Patients on Anti-platelet for Lehigh Valley Physician’s Practice The percentage of patients 





Figure 5: Percentage of Patients on Antiplatelet for Emmaus Family Medicine The percentage of patients on anti-
platelet began at 67.7% and ended at 78.1%, an increase of 10.4%. The goal of 77.7% was met. Intervention 





Figure 6: Percentage of Patients on Anti-platelet for Cedar Crest Cardiology The percentage of patients on anti-





Figure 7: Percentage of Patients on Anti-platelet for 1251 Cedar Crest Family Medicine The percentage of patients 
on anti-platelet began at 74.3% and ended at 85.6%, an increase of 11.3%. The goal of 77.7% was met. Intervention 





Figure 8: Percentage of Patients on Anti-platelet for Hamburg Cardiology The percentage of patients on anti-
platelet began at 61.0% and ended at 88.6%, an increase of 27.6%. The goal of 77.7% was met. Intervention 




Beta Blocker Quality Metric 
Practices reviewed for the beta blocker quality metric 
were Cedar Crest Cardiology and 1251 Cedar Crest 
Family Medicine. Family medicine was completed 
independently by practice staff through use of 
education tools provided so the data is not included in 
Table 2.  A total of 72 charts were reviewed with 
5/72 or 6.9% not currently or previously taking a beta 





Table 2: Summary of Data for All Practices for Beta-Blocker Quality Metric 
Possible Clinical Contraindications Percentage of Total Patients Reviewed 




Allergy  1.4% 
Beta-blocker listed in past notes 76.4% 
Procedural Issues Percentage of Total Patients Reviewed 
Medications not transferred 80.6% 
No upcoming appointment 83.3% 
Patients not seen in the past year 41.7% 
 
*Some patients have more than one possible contraindication 
9 
 
Figure 9: Percentage of Patients on a Beta-Blocker for Cedar Crest Cardiology The percentage of patients on a 
beta blocker began at 77.6% and ended at 93.9%, an increase of 16.3%. The goal of 83.4% was met. Intervention 





Figure 10: Percentage of Patients on a Beta-Blocker for 1251 Cedar Crest Family Medicine The percentage of 
patients on a beta-blocker began at 91.7% and ended at 100.0%, an increase of 8.3%. The goal of 83.4% was met. 





ACE Inhibitor/ARB Quality Metric 
Practices reviewed for the ACE/ARB quality metric 
were Hamilton Internal Medicine, LVPG Family and 
Internal medicine Bethlehem Township, and Cedar 
Crest Internal Medicine. Hamilton Internal Medicine 
was the only practice with data inputted into EPIC. A 
total of 212 charts were reviewed. The percentage of 
patients not currently or previously taking ACE/ARB 
was not recorded due to the different approach for 
this metric. Initially, a practice dashboard was not 
available so a large database was used.
 
 
Table 3: Summary of Data for All Practices for ACE/ARB Quality Metric 
Possible Clinical Contraindications Percentage of Total Patients Reviewed 





Procedural Issues Percentage of Total Patients Reviewed 
Medications not transferred 9.4% 
No upcoming appointment 30.7% 





Figure 11: Percentage of Patients on an ACE inhibitor/ARB for 3080 Hamilton Internal Medicine The percentage 
of patients on an ACE/ARB began at 65.8% and ended at 69.9%, an increase of 4.1%. Intervention occurred the 
week of June 28
th
. Various slopes and non-linear trends can be observed due to changes in the definition for the 
metric and thus the population. Beginning the week of July 20
th
 the correct definition was implemented. 
Discussion 
An overall analysis of the data for each 
metric clearly demonstrates specific data issues and 
clinical contraindications are the likely causes for 
non-adherence with metric guidelines. For patients 
with a diagnosis of IVD who should be prescribed an 
anti-platelet therapy, 39.8% did not have an updated 
medication list in EPIC. This allowed for a fairly 
quick clean-up of the data by providing each contact 
person a list of patient MRNs that needed 
medications lists to be reconciled. The most common 
antiplatelet metric relative contraindication, 31.4% of 
patients, was the additional prescription of a blood 
thinner. To address this, education tools were 
developed that include research supporting the use of 
dual therapy and calculators for assessing bleeding 
risk, to encourage appropriate management where 
indicated. Additional information for each 
contraindication was included in the developed 
education tools. It was also found that 39.8% of 
patients did not have an upcoming appointment. This 
is potentially problematic for future metric analysis, 
as appointments are needed to discuss and prescribe 
medications. To address this problem, patients 
without future appointments were noted in the data 
provided to each practice. A unique problem for 
cardiology practices is that EPIC currently does not 
allow for easy review of individual cardiologists’ 
patients, as it does for PCPs. Additionally, as 
consultative practices, patients are seen less 
frequently and often have PCPs outside of LVPG, 
resulting in less patient data in EPIC. The review of 
733 charts for the antiplatelet metric led to increases 
in the metric compliance percentage for all practices 
with an average increase of 11.0%. When analyzing 
the graphs in EPIC, it is important to consider the 
population size. Smaller practices show more of an 
increase in the patient adherence percentages. 
 Similar trends were observed for the beta-
blocker metric, with 80.6% of patients not having 
transferred medication lists and 83.3% not having an 
upcoming appointment. Due to time constraints, the 
beta-blocker metric was only analyzed for one 
practice. The contact at 1251 Cedar Crest Family 
Medicine was taught how to follow the standardized 
protocol, and the results reflect their work. The most 
12 
common contraindication for beta-blockers was an 
intolerance to the medication, most often fatigue. As 
a result of the project, the percentages of patients on 
beta-blockers at three practices now meet Medicare’s 
Metric standard of 83.4%. Rapid improvement of this 
metric was partially a result of the small number of 
patients requiring a beta-blocker and the limited 
number of contraindications.  
 The ACE inhibitor/ARB metric proved to be 
difficult due to the multiple changes made in the 
EPIC definition of patients included in the metric. 
Initially, diabetic patients were not included, 
resulting in approximately 90% of the patient 
population indicated for ACE inhibitors/ARBs to not 
be listed in the report. It was found that clinical 
contraindications were the most commonly cited 
reason (18.9%) for non-compliance with this metric. 
A high percentage of patients (30.7%) again did not 
have upcoming appointments. Analysis of each 
practice’s graph shows inconsistent and non-linear 
trends, associated with the changing definitions. For 
this reason it cannot be determined how this project 
influenced the metric. Beginning the week of July 
20
th
 the metric definition began to also include 
patients with CAD and diabetes. Therefore, only the 









 The results of this quality improvement 
project show promise and effectiveness for the future. 
Generating EPIC reports and subsequently reviewing 
patient charts provides an efficient workflow for 
quality metric improvement. To ensure the 
sustainability of this work, multiple education tools 
have been developed. To decrease provider 
difficulties with accurate documentation and chart 
review, a collection of power-points were developed: 
step-by-step EPIC screenshot instructions for 
documenting allergies, intolerances, 
contraindications, and declinations, as well as a 
detailed PowerPoint for how to generate, customize, 
and filter reports for each metric.  
 To enable any qualified professional in a 
practice to conduct quality metric improvement, 
workflows were created in both a single page format 
and a more detailed booklet. It is recommended 
responsible person in each practice is identified to 
review reports regularly, first to improve the 
registries by updating medications, then to focus on 
patients with upcoming appointments not receiving 
standard of care medications. Once each metric 
reaches the preset goal, periodic review is 
recommended. Overall, the goal of quality metric 
improvement for CAD, CHF, and IVD measures was 
achieved, and a variety of tools were developed to 
ensure continued sustainability of improvement of 
evidence-based care metrics. 
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